Cymra completes
Musculoskeletal Chronic Neck and Back Pain Phase II study

Clinical Development Program



  • Cymra has now COMPLETED its Phase II Dose Escalation Study
  • This open label Phase II dose-ranging study has been conducted to demonstrate the safety and tolerability of oral administration of Cybis oil in patients with moderate to severe chronic back or neck pain unresponsive to over-the- counter (OTC) analgesics.
  • The study also investigates the dose-response relationship of Cybis 10:25 oil in terms of pain relief and quality of life outcomes in this patient population and examines the pharmacokinetics of Cybis 10:25 oil after single and repeat dose

GMP Australian grown and manufactured cannabis oil

  • The clinical product, Cybis 10:25 oil is a formulated full spectrum medicinal cannabis product. The product is manufactured in Australia under GMP conditions.
  • The product consists of two cannabis strains for CBD and THC
  • It is also EU GMP compliant


  • Twenty-eight patients with moderate to severe chronic back and neck pain unresponsive to OTC analgesics have completed the four-week dosing period.
  • Doses of CybisTM 10:25 oil will increase weekly in all patients from 0.5 mL once daily to 0.5 mL twice daily, 1.0 mL twice daily, and 1.5 mL twice daily, as tolerated.
  • Patients are assessed at the end of each one-week dose period for safety and tolerability with a physical examination and recording of adverse effects. Pain response, depression / anxiety / stress, sleep quality, and overall treatment satisfaction are also assessed at the end of each dose period using validated assessment tools.
  • Pharmacokinetic analyses are undertaken after the first dose, and after the last dose at each dose level.
  • The results of the study demonstrate the safety of Cybis 10:25 oil in this population and provide information on the dose response relationship of Cybis 10:25 oil to support dose selection and calculation of patient numbers for a pivotal Phase III randomised controlled trial to be commenced in 2024


  • Results have been published in a peer reviewed journal
  • Reduction in pain scores
  • Cymra has statistical significance at all dose levels
  • Clear dose response
  • Minimal adverse effects
  • Understanding of bioavailability, toxicity and safety data
  • Improvements in quality of life

Next steps

  • Cymra has developed a Phase III clinical trial protocol
  • Over 200 patient study double blinded placebo controlled study
  • Funding is now being sought
  • Hopeful to commence early 2024

Medical Cannabis Information and Updates

Want to keep up to date with the latest Medical Cannabis Information in Australia and from around the world? We will send you informative information from time to time so you can learn about cannabis and if it can help you.